GYRE GYRE THERAPEUTICS, INC.companySEC Filings & Insider Trading Activity 2026
Latest GYRE THERAPEUTICS, INC. (GYRE) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 13, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on April 17, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for GYRE THERAPEUTICS, INC. (GYRE) (SEC CIK 1124105), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings announced March 12, 2026; details in Exhibit 99.1 press release
- • Filing covers fiscal year ended December 31, 2025 — annual results, not just a quarterly update
Recent 8-K FilingsCurrent Reports
AI-powered analysis of GYRE THERAPEUTICS, INC. (GYRE) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 17, 2026 | — | — | — |
8-K | Mar 23, 2026 | — | — | — |
10-K | Mar 13, 2026 | Dec 31, 2025 | — | |
8-K | Mar 12, 2026 | — | Analysis | — |
8-K | Mar 12, 2026 | — | Analysis | — |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Jan 5, 2026 | — | — | |
10-Q | Nov 7, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 9, 2025 | Mar 31, 2025 | — | |
10-K | Mar 17, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Mar 27, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 15, 2023 | Mar 31, 2023 | — | |
10-K | Mar 30, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 14, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 15, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Mar 31, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 12, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest GYRE SEC filings in 2026?
GYRE THERAPEUTICS, INC. (GYRE) has filed a 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did GYRE file its most recent 10-K annual report?
GYRE THERAPEUTICS, INC. (GYRE) filed its most recent 10-K annual report on March 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view GYRE 10-Q quarterly reports?
GYRE THERAPEUTICS, INC. (GYRE)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every GYRE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has GYRE filed recently?
GYRE THERAPEUTICS, INC. (GYRE)'s most recent 8-K was filed on April 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find GYRE insider trading activity (Form 4)?
SignalX aggregates every GYRE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does GYRE file with the SEC?
GYRE THERAPEUTICS, INC. (GYRE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GYRE filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GYRE THERAPEUTICS, INC. (GYRE).
What is GYRE's SEC CIK number?
GYRE THERAPEUTICS, INC. (GYRE)'s SEC CIK (Central Index Key) number is 1124105. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1124105 to look up all GYRE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find GYRE return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from GYRE THERAPEUTICS, INC. (GYRE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of GYRE THERAPEUTICS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 60+ filings.